Skip to main content
Top
Published in: Health Economics Review 1/2012

Open Access 01-12-2012 | Review

Methodological considerations in cost of illness studies on Alzheimer disease

Authors: Nagede Costa, Helene Derumeaux, Thomas Rapp, Valérie Garnault, Laura Ferlicoq, Sophie Gillette, Sandrine Andrieu, Bruno Vellas, Michel Lamure, Alain Grand, Laurent Molinier

Published in: Health Economics Review | Issue 1/2012

Login to get access

Abstract

Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.
Appendix
Available only for authorised users
Literature
2.
go back to reference Koopmanschap MA: Cost of illness studies: Useful for health policy? PharmacoEconomics 1998,14(2):143–148. 10.2165/00019053-199814020-00001PubMedCrossRef Koopmanschap MA: Cost of illness studies: Useful for health policy? PharmacoEconomics 1998,14(2):143–148. 10.2165/00019053-199814020-00001PubMedCrossRef
3.
go back to reference Hogdson TA: Annual costs of illness versus Lifetime costs of illness and implications of structural change. Drug Inf J 1988, 22: 323–341. Hogdson TA: Annual costs of illness versus Lifetime costs of illness and implications of structural change. Drug Inf J 1988, 22: 323–341.
4.
go back to reference Alzheimer’s Association Reports: 2011 Alzheimer's disease facts and figures. W V Med J 2011,107(3):82–83. Alzheimer’s Association Reports: 2011 Alzheimer's disease facts and figures. W V Med J 2011,107(3):82–83.
5.
go back to reference Wimo A, Prince M: World Alzheimer Report 2011, The global Economic Impact of Dementia. Alzheimer Disease Int 2010, 1–52. Wimo A, Prince M: World Alzheimer Report 2011, The global Economic Impact of Dementia. Alzheimer Disease Int 2010, 1–52.
6.
go back to reference O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S: Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. Journal Am Gerriatr soc 1999,47(5):570–578.CrossRef O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S: Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. Journal Am Gerriatr soc 1999,47(5):570–578.CrossRef
7.
go back to reference Hill JW, Futterman R, Mastey V, Fillit H: The effect of donepezil therapy on health costs in a Medicare managed plan. Manag Care Interface 2002,15(3):63–70.PubMed Hill JW, Futterman R, Mastey V, Fillit H: The effect of donepezil therapy on health costs in a Medicare managed plan. Manag Care Interface 2002,15(3):63–70.PubMed
8.
go back to reference Jönsson L, Wimo A: The cost of dementia in Europe: a review of the evidence, and methodological considerations. PharmacoEconomics 2009,27(5):391–403. 10.2165/00019053-200927050-00004PubMedCrossRef Jönsson L, Wimo A: The cost of dementia in Europe: a review of the evidence, and methodological considerations. PharmacoEconomics 2009,27(5):391–403. 10.2165/00019053-200927050-00004PubMedCrossRef
9.
go back to reference Mauskopf J, Mucha L: A review of the methods used to estimate the cost of Alzheimer's disease in the United States. Am J Alzheimers Dis Other Demen 2011,26(4):298–309. 10.1177/1533317511407481PubMedCrossRef Mauskopf J, Mucha L: A review of the methods used to estimate the cost of Alzheimer's disease in the United States. Am J Alzheimers Dis Other Demen 2011,26(4):298–309. 10.1177/1533317511407481PubMedCrossRef
10.
go back to reference McDaid D: Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Psychiatry 2001,16(4):400–405. 10.1002/gps.353PubMedCrossRef McDaid D: Estimating the costs of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Psychiatry 2001,16(4):400–405. 10.1002/gps.353PubMedCrossRef
11.
go back to reference Drummond MF: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford: Oxford University Press; 2005. Drummond MF: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford: Oxford University Press; 2005.
12.
go back to reference Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, Daurès JP, Grosclaude P: Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 2008,11(5):878–885. 10.1111/j.1524-4733.2008.00327.xPubMedCrossRef Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, Daurès JP, Grosclaude P: Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health 2008,11(5):878–885. 10.1111/j.1524-4733.2008.00327.xPubMedCrossRef
13.
go back to reference Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J: Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006,26;67(12):2186–2191.CrossRef Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J: Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 2006,26;67(12):2186–2191.CrossRef
14.
go back to reference Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, López-Pousa S, López-Arrieta JM, Del Llano J, León T, Rejas J: Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis 2010,19(2):601–615.PubMed Coduras A, Rabasa I, Frank A, Bermejo-Pareja F, López-Pousa S, López-Arrieta JM, Del Llano J, León T, Rejas J: Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study. J Alzheimers Dis 2010,19(2):601–615.PubMed
15.
go back to reference Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F: Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neuro 2003,16(3):140–145. 10.1177/0891988703252558CrossRef Rigaud AS, Fagnani F, Bayle C, Latour F, Traykov L, Forette F: Patients with Alzheimer's disease living at home in France: costs and consequences of the disease. J Geriatr Psychiatry Neuro 2003,16(3):140–145. 10.1177/0891988703252558CrossRef
16.
go back to reference Kronborg Andersen C, Søgaard J, Hansen E, Kragh-Sørensen A, Hastrup L, Andersen J, Andersen K, Lolk A, Nielsen H, Kragh-Sørensen P: The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999,10(4):295–304. 10.1159/000017135PubMedCrossRef Kronborg Andersen C, Søgaard J, Hansen E, Kragh-Sørensen A, Hastrup L, Andersen J, Andersen K, Lolk A, Nielsen H, Kragh-Sørensen P: The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999,10(4):295–304. 10.1159/000017135PubMedCrossRef
17.
go back to reference Cavallo MC, Fattore G: The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997,11(4):184–190.PubMed Cavallo MC, Fattore G: The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997,11(4):184–190.PubMed
18.
go back to reference Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L: Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 2010,7(4):358–367. 10.2174/156720510791162430PubMedCrossRef Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L: Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 2010,7(4):358–367. 10.2174/156720510791162430PubMedCrossRef
19.
go back to reference Kiencke P, Dietmar D, Grimm C, Rychlik R: Direct costs of Alzheimer disease in Germany. Eur J Health Econ 2011, 12: 533–539. 10.1007/s10198-010-0267-xPubMedCrossRef Kiencke P, Dietmar D, Grimm C, Rychlik R: Direct costs of Alzheimer disease in Germany. Eur J Health Econ 2011, 12: 533–539. 10.1007/s10198-010-0267-xPubMedCrossRef
20.
go back to reference Leon J, Neumann PJ: The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999,5(7):867–877.PubMed Leon J, Neumann PJ: The cost of Alzheimer's disease in managed care: a cross-sectional study. Am J Manag Care 1999,5(7):867–877.PubMed
22.
go back to reference Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E: The economic burden of Alzheimer's disease care. Health Aff 1993,12(2):164–176. 10.1377/hlthaff.12.2.164CrossRef Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, Segura E: The economic burden of Alzheimer's disease care. Health Aff 1993,12(2):164–176. 10.1377/hlthaff.12.2.164CrossRef
23.
go back to reference Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: costs and potential savings. Health Aff 1998,17(6):206–216. 10.1377/hlthaff.17.6.206CrossRef Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: costs and potential savings. Health Aff 1998,17(6):206–216. 10.1377/hlthaff.17.6.206CrossRef
24.
go back to reference Ostbye T, Crosse E: Net economic costs of dementia in Canada. CMAJ 1994,15;151(10):1457–1464. Ostbye T, Crosse E: Net economic costs of dementia in Canada. CMAJ 1994,15;151(10):1457–1464.
25.
go back to reference Zencir M, Kuzu N, Beşer NG, Ergin A, Catak B, Sahiner T: Cost of Alzheimer's disease in a developing country setting. Int J Geriatr Psychiatry 2005,20(7):616–622. 10.1002/gps.1332PubMedCrossRef Zencir M, Kuzu N, Beşer NG, Ergin A, Catak B, Sahiner T: Cost of Alzheimer's disease in a developing country setting. Int J Geriatr Psychiatry 2005,20(7):616–622. 10.1002/gps.1332PubMedCrossRef
26.
go back to reference Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui PJ, Zhang T, Sun ZK, Ren RJ, Deng YL, Xu W, Wang Y, Chen SD: Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimers Dis 2008,15(1):109–115.PubMed Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui PJ, Zhang T, Sun ZK, Ren RJ, Deng YL, Xu W, Wang Y, Chen SD: Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China. J Alzheimers Dis 2008,15(1):109–115.PubMed
27.
go back to reference Suh GH, Knapp M, Kang CJ: The economic costs of dementia in Korea, 2002. Int J Geriatr Psychiatry 2006,21(8):722–728. 10.1002/gps.1552PubMedCrossRef Suh GH, Knapp M, Kang CJ: The economic costs of dementia in Korea, 2002. Int J Geriatr Psychiatry 2006,21(8):722–728. 10.1002/gps.1552PubMedCrossRef
28.
go back to reference Beeri MS, Werner P, Adar Z, Davidson M, Noy S: Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord 2002,16(2):73–80. 10.1097/00002093-200204000-00004PubMedCrossRef Beeri MS, Werner P, Adar Z, Davidson M, Noy S: Economic cost of Alzheimer disease in Israel. Alzheimer Dis Assoc Disord 2002,16(2):73–80. 10.1097/00002093-200204000-00004PubMedCrossRef
29.
go back to reference Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, Sarasola D, Lon L: Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 2007,19(4):705–718. 10.1017/S1041610206003784PubMedCrossRef Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano FE, Sarasola D, Lon L: Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr 2007,19(4):705–718. 10.1017/S1041610206003784PubMedCrossRef
30.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984,34(7):939–944. 10.1212/WNL.34.7.939PubMedCrossRef McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984,34(7):939–944. 10.1212/WNL.34.7.939PubMedCrossRef
31.
go back to reference American Psychiatric Association: Diagnostic and Statistical Manual of Mental disorders. 4th edition. Washington DC: American Psychiatric Association; 2000. American Psychiatric Association: Diagnostic and Statistical Manual of Mental disorders. 4th edition. Washington DC: American Psychiatric Association; 2000.
32.
go back to reference Quentin W, Riedel-Heller S, Luppa M, Rudolph A, König HH: Cost of illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psyciatra Scandinavia 2010, 121: 243–259. 10.1111/j.1600-0447.2009.01461.xCrossRef Quentin W, Riedel-Heller S, Luppa M, Rudolph A, König HH: Cost of illness studies of dementia: a systematic review focusing on stage dependency of costs. Acta Psyciatra Scandinavia 2010, 121: 243–259. 10.1111/j.1600-0447.2009.01461.xCrossRef
33.
go back to reference Small GW, McDonnell DD, Brooks RL, Papadopoulos G: The impact of symptom severity on the cost of Alzheimer disease. Journal American Geriatric society 2002,50(2):321–327. 10.1046/j.1532-5415.2002.50065.xCrossRef Small GW, McDonnell DD, Brooks RL, Papadopoulos G: The impact of symptom severity on the cost of Alzheimer disease. Journal American Geriatric society 2002,50(2):321–327. 10.1046/j.1532-5415.2002.50065.xCrossRef
34.
go back to reference Mauskopf J, Racketa J, Sherrill E: Alzheimer’s disease: the strength of association of costs with different measures of disease severity. J Nutr Health Aging 2010,14(8):655–663. 10.1007/s12603-010-0312-6PubMedCrossRef Mauskopf J, Racketa J, Sherrill E: Alzheimer’s disease: the strength of association of costs with different measures of disease severity. J Nutr Health Aging 2010,14(8):655–663. 10.1007/s12603-010-0312-6PubMedCrossRef
35.
go back to reference Herman N, Tam DY, Balshaw R, Sambrook R, Lesnikova N, Lanctôt KL: Canadian Outcomes Study in Dementia [COSID] Investigators, The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can J Psychiatry 2010,55(12):768–775. Herman N, Tam DY, Balshaw R, Sambrook R, Lesnikova N, Lanctôt KL: Canadian Outcomes Study in Dementia [COSID] Investigators, The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can J Psychiatry 2010,55(12):768–775.
36.
go back to reference Morris JC: The Clinical Dementia Rating [CDR]: current version and scoring rules. Neurology 1983, 43: 2412–2414.CrossRef Morris JC: The Clinical Dementia Rating [CDR]: current version and scoring rules. Neurology 1983, 43: 2412–2414.CrossRef
37.
go back to reference Crum RM, Anthony JC, Bassett SS, Folstein MF: Population-based norms for the mini-mental state examination by age and educational level. JAMA 1993, 269: 2386–2389. 10.1001/jama.1993.03500180078038PubMedCrossRef Crum RM, Anthony JC, Bassett SS, Folstein MF: Population-based norms for the mini-mental state examination by age and educational level. JAMA 1993, 269: 2386–2389. 10.1001/jama.1993.03500180078038PubMedCrossRef
38.
go back to reference Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y: Longitudinal study of effects on patient characteristics on direct costs in Alzheimer disease. Neurology 2006,67(6):998–1005. 10.1212/01.wnl.0000230160.13272.1bPubMedCrossRef Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y: Longitudinal study of effects on patient characteristics on direct costs in Alzheimer disease. Neurology 2006,67(6):998–1005. 10.1212/01.wnl.0000230160.13272.1bPubMedCrossRef
39.
go back to reference Tarricone R: Cost of illness analysis. What room in health economics. Health Policy 2006, 77: 51–63. 10.1016/j.healthpol.2005.07.016PubMedCrossRef Tarricone R: Cost of illness analysis. What room in health economics. Health Policy 2006, 77: 51–63. 10.1016/j.healthpol.2005.07.016PubMedCrossRef
40.
go back to reference Koopmanschap MA, Rutten FF: Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 1993, 4: 446–454. 10.2165/00019053-199304060-00006PubMedCrossRef Koopmanschap MA, Rutten FF: Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 1993, 4: 446–454. 10.2165/00019053-199304060-00006PubMedCrossRef
41.
go back to reference Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating costs of disease. Soc Sci Med 1992,34(9):1005–1010. 10.1016/0277-9536(92)90131-9PubMedCrossRef Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating costs of disease. Soc Sci Med 1992,34(9):1005–1010. 10.1016/0277-9536(92)90131-9PubMedCrossRef
42.
go back to reference Hogdson TA, Meiners MR: Cost of illness methodology a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982,60(3):429–462. 10.2307/3349801CrossRef Hogdson TA, Meiners MR: Cost of illness methodology a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982,60(3):429–462. 10.2307/3349801CrossRef
43.
go back to reference Van der Berg B, Brouwer W, Van Exel J, Koopmanschap M, Van den Bos GAM, Rutten F: Economic valuation of informal care: lessons from the application of the opportunity costs and proxy goods methods. Soc Sci Med 2006, 62: 835–845. 10.1016/j.socscimed.2005.06.046CrossRef Van der Berg B, Brouwer W, Van Exel J, Koopmanschap M, Van den Bos GAM, Rutten F: Economic valuation of informal care: lessons from the application of the opportunity costs and proxy goods methods. Soc Sci Med 2006, 62: 835–845. 10.1016/j.socscimed.2005.06.046CrossRef
44.
go back to reference Koopmanschap MA, Van Exel JN, Van den Berg B, Brouwer WB: An overwiew of methods and application to value informal care in economic evaluation of healthcare. PharmacoEconomics 2008,26(4):269–280. 10.2165/00019053-200826040-00001PubMedCrossRef Koopmanschap MA, Van Exel JN, Van den Berg B, Brouwer WB: An overwiew of methods and application to value informal care in economic evaluation of healthcare. PharmacoEconomics 2008,26(4):269–280. 10.2165/00019053-200826040-00001PubMedCrossRef
45.
go back to reference Gold MR, Russel LB, Siegel JE, Daniels N, Weinstein MC: Cost effectiveness in Health and Medicine. JAMA 1996,276(14):1172–1177. 10.1001/jama.1996.03540140060028PubMedCrossRef Gold MR, Russel LB, Siegel JE, Daniels N, Weinstein MC: Cost effectiveness in Health and Medicine. JAMA 1996,276(14):1172–1177. 10.1001/jama.1996.03540140060028PubMedCrossRef
46.
go back to reference Agro KE, Bradley CA, Mittmann N, et al.: Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature. Pharmacoeconomics 1997, 11: 75–88. 10.2165/00019053-199711010-00009PubMedCrossRef Agro KE, Bradley CA, Mittmann N, et al.: Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature. Pharmacoeconomics 1997, 11: 75–88. 10.2165/00019053-199711010-00009PubMedCrossRef
47.
go back to reference Wiseman V, Mooney G: Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998, 43: 243–251. 10.1016/S0168-8510(98)00003-7PubMedCrossRef Wiseman V, Mooney G: Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998, 43: 243–251. 10.1016/S0168-8510(98)00003-7PubMedCrossRef
48.
go back to reference Wimo A, Nordberg G, Jansson W, Grafström M: Assessment of informal services to demented people with the RUD instrument. Int J Geriatr Psychiatry 2000,15(10):969–971. 10.1002/1099-1166(200010)15:10<969::AID-GPS272>3.0.CO;2-9PubMedCrossRef Wimo A, Nordberg G, Jansson W, Grafström M: Assessment of informal services to demented people with the RUD instrument. Int J Geriatr Psychiatry 2000,15(10):969–971. 10.1002/1099-1166(200010)15:10<969::AID-GPS272>3.0.CO;2-9PubMedCrossRef
49.
go back to reference Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL: The Caregiver Activity Survey [CAS]: development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997,12(10):978–988. 10.1002/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1PubMedCrossRef Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL: The Caregiver Activity Survey [CAS]: development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997,12(10):978–988. 10.1002/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1PubMedCrossRef
50.
go back to reference Clipp EC, Moore MJ: Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995,58(2):228–236. 10.1016/0009-9236(95)90201-5PubMedCrossRef Clipp EC, Moore MJ: Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther 1995,58(2):228–236. 10.1016/0009-9236(95)90201-5PubMedCrossRef
53.
go back to reference Schreyer P, Koechlin F: Purchasing power parities: measurement and uses. Statistics breaf. OECD Statistics brief 2002, 3: 1–8. Schreyer P, Koechlin F: Purchasing power parities: measurement and uses. Statistics breaf. OECD Statistics brief 2002, 3: 1–8.
Metadata
Title
Methodological considerations in cost of illness studies on Alzheimer disease
Authors
Nagede Costa
Helene Derumeaux
Thomas Rapp
Valérie Garnault
Laura Ferlicoq
Sophie Gillette
Sandrine Andrieu
Bruno Vellas
Michel Lamure
Alain Grand
Laurent Molinier
Publication date
01-12-2012
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2012
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/2191-1991-2-18

Other articles of this Issue 1/2012

Health Economics Review 1/2012 Go to the issue